Phase 1
Completed N=60
Study to Investigate the Pharmacokinetic Profile
Healthy Male Subjects
Source: ClinicalTrials.gov NCT03286829 ↗
Enrolled (actual)
60
Serious AEs
0.0%
Results posted
May 2020
Primary outcomePrimary: AUC0-48 — 32.06; 6.491; 45.89; 30.14 ng*hr/mL
Summary
A randomized, open-label, single-dose, parallel-arm, Phase 1 study to investigate the pharmacokinetic profile of a fixed-dose combination tablet of tesofensine and metoprolol (Tesomet) and co-administration of tesofensine plus commercial metoprolol in adult healthy subjects
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY AUC0-48 |
32.06; 6.491; 45.89; 30.14 | — |
| SECONDARY Cmax |
0.9528; 0.1934; 1.357; 0.8085 | — |
| SECONDARY Tmax |
6.12; 6.00; 6.00; 8.00 | — |
Eligibility Criteria
Inclusion Criteria
- Subject voluntarily agrees to participate in this study and signs an Independent Ethics Committee (IEC)-approved informed consent prior to performing any of the Screening Visit procedures.
- Males between 18 to 55 years of age, inclusive, at the Screening Visit.
- Nonsmokers (or other nicotine use) as determined by history (no nicotine use over the past 6 months) and by urine cotinine concentration (< 500 ng/mL) at the Screening Visit and admission.
- BMI between 18.5 and 30.0 kg/m2, inclusive, at the Screening Visit.
- Healthy, determined by pre-study medical evaluation (medical history, physical examination, vital signs, 12-lead ECG and clinical laboratory evaluations).
Exclusion Criteria
- Subject has history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or malignancy as judged by the Investigator.
- Subject has any disorder that would interfere with the absorption, distribution, metabolism or excretion of drugs.
- Subject has history of alcohol and/or illicit drug abuse within 2 years of entry.
- Subject is unwilling to avoid consumption of coffee and caffeine-containing beverages within 48 hours prior to admission until discharge from the clinical site.
- Subject is unwilling to avoid use of alcohol or alcohol-containing foods, medications or beverages, within 48 hours prior to admission until discharge from the clinical site.
Data sourced from ClinicalTrials.gov (NCT03286829). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.